Philadelphia, PA, USA — July 27, 2026 — The GOG Foundation, Inc. announced the enrollment of the first patient in GOG-3132/BEHOLD-Ovarian01 (NCT07286266), a global Phase 3 trial evaluating mocertatug rezetecan against standard-of-care chemotherapy in participants with platinum-resistant ovarian cancer. Sponsored by GSK and conducted in collaboration with The GOG Foundation, the study marks a key translational step for a next-generation targeted antibody-drug conjugate (ADC).
BEHOLD-Ovarian01 is designed to determine whether mocertatug rezetecan can improve clinically meaningful outcomes in a population facing limited therapeutic options. The trial follows encouraging activity reported from the Phase 1 BEHOLD-1 study, where responses were observed across patient subgroups relevant to real-world platinum-resistant disease.
Mocertatug rezetecan (Mo-Rez; GSK5733584) targets B7-H4, an immune checkpoint receptor expressed in approximately 70–90% of ovarian cancers but with minimal expression in most normal adult tissues. This differential expression is intended to create a favorable therapeutic window for selective ADC delivery.
Mechanistically, Mo-Rez pairs a B7-H4–directed monoclonal antibody with a topoisomerase I inhibitor payload. After binding to B7-H4–expressing tumor cells, the ADC is internalized, delivering the cytotoxic payload to disrupt DNA replication and drive tumor cell death.
In BEHOLD-1, the Phase 3 dose selection was 5.8 mg/kg. At that dose, the confirmed objective response rate was 62%, with responses spanning a range of B7-H4 expression levels. Notably, activity was also reported in clinically relevant groups, including patients previously treated with bevacizumab and PARP inhibitors.
The trial population in BEHOLD-Ovarian01 reflects a previously treated setting, where platinum-resistant ovarian cancer remains difficult to manage. Standard approaches often rely on non-platinum chemotherapy such as weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan, with or without bevacizumab.
The Phase 3 design is randomized, open-label, and multicenter, comparing Mo-Rez with investigator’s choice chemotherapy. Study stakeholders include global cooperative groups such as ENGOT, APGOT, and LACOG, with The GOG Foundation contributing trial leadership and operational expertise.
Collectively, BEHOLD-Ovarian01 aims to establish whether B7-H4–targeted ADC therapy can translate early pharmacology and antitumor signals into improved progression-free and overall survival for patients with platinum-resistant ovarian cancer.
Subject of Research: People; clinical trial in platinum-resistant ovarian cancer
Article Title: GOG-3132/BEHOLD-Ovarian01 Enrolls First Patient to Test Mocertatug Rezetecan in Platinum-resistant Ovarian Cancer
News Publication Date: July 27, 2026
Web References: http://www.gog.org ; https://engot.esgo.org/ ; NCT07286266
References: Included in the source content (Oaknin A et al., Porter JM et al., and multiple ovarian cancer treatment references)
Image Credits: The GOG Foundation, Inc.
Keywords: mocertatug rezetecan; GSK5733584; B7-H4; antibody-drug conjugate; ovarian cancer; platinum-resistant; Phase 3; BEHOLD-Ovarian01; NCT07286266; ENGOT
Tags: ADC therapy for platinum-resistant ovarian cancerB7-H4 immune checkpoint in ovarian cancerGOG-3132/BEHOLD-Ovarian01 trialGSK mocertatug rezetecan studymocertatug rezetecan clinical trialmonoclonal antibody-drug conjugates in oncologynovel treatments for resistant ovarian cancerovarian cancer therapeutic developmentPhase 3 ovarian cancer trialplatinum-resistant ovarian cancertargeted antibody-drug conjugate for ovarian cancer
